Treatment of Burkitt's Like Lymphoma: A Single Institution Case Series

Abstract

Abstract 4962Background: Burkits's like (BL) lymphoma is a new pathologic entity with features partially resembling to Burkitt's lymphoma and diffuse large B cell lymphoma. The incidence of BL lymphoma is infrequent and may present with lymph node enlargement, involvement of bone marrow and peripheral blood. The natural history of BL lymphoma and its treatment remains unclear. Here we present a single institution case series of five patients diagnosed with BL lymphoma and their treatment. Methods: We searched the pathology reports of all patients diagnosed with lymphoma over the last one year. No inclusion or exclusion criteria were used. Results: We identified a total of five patients with diagnosis of BL lymphoma. All patients presented with lymphadenopathy and with no involvement of bone marrow, central nervous system or peripheral blood. Table 1 summarizes characteristics of all patients, their chemotherapy regimen and subsequent response to treatment. Conclusion: BL lymphoma is a new pathologic entity with low incidence. Treatment with DA-EPOCH and R-HyperCVAD has very good response rate. The data is limited by single institution case series and limited follow up time. Further studies are recommended to evaluate optimal chemotherapy regimen. Table 1: Characteristics, presentation, treatment and response in patients with BL lymphomaNoAgeSexLDH,PresentationTreatmentResponseDuration of response168F386Parotid and abdominal lymphadenopathyDA-R-EPOCHCR16months2^44M536Neck, Axillary, media, abdomen pelvis and sacral metsR-HyperCVADPR3months3*66F310Inguinal and pelvic lymphadenopathyR-HyperCVAD f/b Autologus BMT,CR14months4**71M237Parotid mass3 cycles of DA-EPOCH f/b 3 cycles of R-CHOPCR9months5^52M186Neck LymphadenopathyR-HyperCVADCR3monthsDOX, DOXOL, and anthracenediones in soluble fractions of human myocardial strips after sequential DOX loading/clearance and anthracenedione treatmentNotes: DA-REPOCH: Dose Adjusted Rituximab-Etoposide, Vincristine, Cyclophosphamide, Doxorubicine, Prednisone, R-HyperCVAD: Rituximab, hyperfractionated Cyclophosphamide, Vincristine, Doxorubicin, Dexamethasone, CR: complete remission, BMT: bone marrow transplantation, R-CHOP: rituximab, doxorubicin, cyclophosphamide, vincristine and prednisone. CNS: central nervous system*patient underwent bone marrow transplant because of relapse at current presentation.**patient was changed from DA EPOCH to R-CHOP as patient was not able to tolerate EPOCH^Epatients are halfway through their treatment cycles and are actively getting treatment Disclosures:No relevant conflicts of interest to declare.